Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/12811
Title: Clinical evaluation of the hepatoprotective effect of Katuki (Picrorhiza kurroa Royle ex Benth.) processed in Guduchi (Tinospora cordifolia Wild.) Miers in patients receiving lipid lowering drugs (Statins)
Authors: Singh, Harbans
Sharma, Y K
Keywords: Drug induced hepatitis
Ayurveda
Hepatoprotective effect
Katuki
Guduchi
Statins
Issue Date: Oct-2011
Publisher: NISCAIR-CSIR, India
Series/Report no.: Int. Cl.8: A01D 14/01, A01D 14/09, A01D 14/10, A01D 1/04, A01D 23/21, A01D 7/52
Abstract: The hypolipidaemic drugs have attracted considerable attention because of their potential to prevent cardiovascular disease by retarding the accelerated atherosclerosis in hyperlipidaemic individuals. Statins are the first choice drugs for primary hyperlipidaemias with raised LDL and total cholesterol levels, with or without raised triglycerides levels, as well as for secondary hypercholesterolemia. Statin therapy is commonly associated with liver damage in terms of elevated aminotransaminases. Simultaneous use of hepatotoxicity reducing formulation is desirable for successful continuation of HMG-CoA reductase inhibitor (statins) over a desired period in hyperlipidaemic patients. So, the present clinical study was planned to evaluate the hepatoprotective effect of Katuki (Picrorhiza kurroa Royle ex Benth.) processed in Guduchi [Tinospora cordifolia (Wild.) Miers], on scientific parameters. In the present clinical trial, two groups of patients receiving standardized lipid lowering drug (Atrorvastatin 20 mg, twice daily) have been studied to evaluate the hepatoprotective effect of these drugs. The first group was given 2 gm of Katuki processed in Guduchi, twice daily with statin therapy. The second group was given 500 mg of starch powder filled in capsules, twice daily with statin therapy. The trial was conducted for three months and liver functions test were periodically evaluated to assess the hepatoprotective effect of drugs under trial. At the end of the trial, trial group exhibited its hepatoprotective efficiency over the control.
Description: 657-660
URI: http://hdl.handle.net/123456789/12811
ISSN: 0975-1068 (Online); 0972-5938 (Print)
Appears in Collections:IJTK Vol.10(4) [October 2011]

Files in This Item:
File Description SizeFormat 
IJTK 10(4) 657-660.pdf70.14 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.